Adhd Portfolio was Aytu Biopharma’s largest segment in fiscal 2026, bringing in $45.83M of $57.57M (80%).
| Segment | FY 2019 | FY 2020 | FY 2021 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|
| Adhd Portfolio | $57.58M | $45.83M | |||
| Consumer Health Portfolio | — | — | |||
| Attention Deficit Hyperactivity Disorder Portfolio | — | — | |||
| Pediatric Portfolio | — | — | |||
| Other Product Portfolio | — | — | |||
| Primary Care & Devices Portfolio | — | — | |||
| Product Revenue | — | — | |||
| The Pediatric Portfolio | $8.77M | $5.14M | |||
| E X X U A Portfolio | — | $6.57M | |||
| License Revenue | — | — | |||
| Product & Service, Other | $37.00K | $36.00K | |||
| Total | $66.38M | $57.57M |
Aytu Biopharma brought in $57.57M from its four segments in fiscal 2026, the year ended June 30, 2026. Aytu Biopharma regrouped these segments after fiscal 2025, so the total does not compare directly with that year's $66.38M. Adhd Portfolio was the largest at $45.83M (79.6%), ahead of E X X U A Portfolio at $6.57M (11.4%) and The Pediatric Portfolio at $5.14M (8.9%). The remaining segment, Product & Service, Other, brought in $36.00K.
Compared with fiscal 2025, Adhd Portfolio fell 20.4% to $45.83M and The Pediatric Portfolio fell 41.4% to $5.14M.
Aytu Biopharma began breaking out E X X U A Portfolio in fiscal 2026, when it brought in $6.57M.
United States was Aytu Biopharma’s largest region in fiscal 2023, bringing in $106.92M of $107.40M (100%).
| Geography | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 |
|---|---|---|---|---|---|---|
| United States | — | $60.69M | $94.61M | $106.92M | ||
| U.S | $24.98M | — | — | — | ||
| Non-Us | — | $4.95M | $2.06M | $481.00K | ||
| International | $2.65M | — | — | — | ||
| Rest-Of-The-World | — | — | — | — | ||
| Total | $27.63M | $65.63M | $96.67M | $107.40M |
Aytu Biopharma brought in $107.40M from its two regions in fiscal 2023, the year ended June 30, 2023. That was up 11.1% from $96.67M in fiscal 2022. United States was the largest at $106.92M (99.6%), ahead of Non-Us at $481.00K (0.4%).
Aytu Biopharma began breaking out United States in fiscal 2021 and Non-Us in fiscal 2021. Aytu Biopharma stopped reporting U.S ($24.98M in fiscal 2020) and International ($2.65M in fiscal 2020) as separate regions.
Aytu Biopharma (AYTU) reports its revenue by segment and by geography. In fiscal 2026, Adhd Portfolio was its largest segment, bringing in $45.83M (79.6% of the total), followed by E X X U A Portfolio at $6.57M (11.4%).
Adhd Portfolio was Aytu Biopharma's largest segment in fiscal 2026, bringing in $45.83M, or 79.6% of the $57.57M total across its four segments.
United States was Aytu Biopharma's largest region in fiscal 2023, bringing in $106.92M, or 99.6% of the $107.40M total across its two regions.
Every figure comes from Aytu Biopharma's annual financial filings, as reported. Each line keeps the name Aytu Biopharma gives it, and years follow its fiscal calendar.
Aytu Biopharma's revenue by segment goes back to fiscal 2019, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.